Back to Article
The Application of Machine Learning in the Corona Era, With an Emphasis on Economic Concepts and Sustainable Development Goals
Table 4. Important Vaccines under development
| Vaccines | Trial phase (1 2 3) | Prior vaccine development experience | Approval status | Pre-orders (Later, -, Soon) | Immune response |
| Astrazeneca-Oxford | 1 2 3 | No | Review | Soon | 70%* |
| Cansino biologics | 1 2 3 | Yes | Limited | Soon | High |
| Gamaleya research institute | 1 2 3 | Yes | Limited | Soon | Moderate |
| Inovio-cepi | 1 2 3 | No | - | Later | Not reported |
| Johnson & Johnson Barda Janssen | 1 2 3 | Yes | - | Later | Moderate |
| Moderna-Niaid | 1 2 3 | No | Review | Soon | 94.5% |
| Novavax | 1 2 3 | No | - | - | High |
| Pfizer-Biontech | 1 2 3 | No | Review | Soon | 95% |
| Sinopharm-Beijing institute of biological products | 1 2 3 | Yes | Limited | - | Moderate |
| Sinovac-instituto Butantan | 1 2 3 | No | - | - | Low |